%PDF-1.4
%
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
11 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
10 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
12 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T04PI2P0T5T0 q-Br44C@B 9 s
(P
endstream
endobj
14 0 obj
<>stream
application/pdf
10.1080/2162402X.2016.1219825
en
Taylor & Francis
OncoImmunology, 2017. doi:10.1080/2162402X.2016.1219825
Cancer vaccine
HLA ligandome
immunotherapy
MyD88 L265P
neoantigen
non-Hodgkin lymphoma
peptide vaccination
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
Annika Nelde
Juliane Sarah Walz
Daniel Johannes Kowalewski
Heiko Schuster
Olaf-Oliver Wolz
Janet Kerstin Peper
Yamel Cardona Gloria
Anton W. Langerak
Alice F. Muggen
Rainer Claus
Irina Bonzheim
Falko Fend
Helmut Rainer Salih
Lothar Kanz
Hans-Georg Rammensee
Stefan Stevanović
Alexander N. R. Weber
Journal
OncoImmunology
Copyright Taylor & Francis
2162-402X
6
3
1
11
10.1080/2162402X.2016.1219825
http://dx.doi.org/10.1080/2162402X.2016.1219825
Arbortext Advanced Print Publisher 10.0.1062/W Unicode
2017-04-07T06:17:20-07:00
2017-03-28T11:27:51+05:30
2017-04-07T06:17:20-07:00
iText 4.2.0 by 1T3XT
Cancer vaccine,HLA ligandome,immunotherapy,MyD88 L265P,neoantigen,non-Hodgkin lymphoma,peptide vaccination
uuid:6abbf790-8a8f-41a3-8dd3-84c55f2eaab8
uuid:9704e91e-9780-4723-b1ed-20edcade88f5
2016-12-23truewww.tandfonline.com10.1080/2162402X.2016.1219825www.tandfonline.comtrue2016-12-2310.1080/2162402X.2016.1219825
endstream
endobj
15 0 obj
<>stream
x+ |
endstream
endobj
16 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
17 0 obj
<>stream
x+ |
endstream
endobj
18 0 obj
<>stream
xS**T0T0 Bi y,
endstream
endobj
19 0 obj
<>stream
x+ |
endstream
endobj
20 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
21 0 obj
<>stream
x+ |
endstream
endobj
22 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
23 0 obj
<>stream
x+ |
endstream
endobj
24 0 obj
<>stream
xS**T0T0 Bi y+
endstream
endobj
25 0 obj
<>stream
x+ |
endstream
endobj
26 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
27 0 obj
<>stream
x+ |
endstream
endobj
28 0 obj
<>stream
xS*
R
endstream
endobj
29 0 obj
<>stream
x+ |
endstream
endobj
30 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
31 0 obj
<>stream
x+ |
endstream
endobj
32 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
33 0 obj
<>stream
x+ |
endstream
endobj
34 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
35 0 obj
<>stream
x+ |
endstream
endobj
36 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
37 0 obj
<>stream
x+ |
endstream
endobj
38 0 obj
<>stream
xS**T0T0 Bih lT
endstream
endobj
40 0 obj
<>stream
x[[$~_/wwψ(_|5RK&yj)&?0Er},S$75)!5514AH)7J*4,kenV%EbMJ(:To*S&MMO/OM߯ϿOM?u_<3 i
}{Vw/No>&
.D[
t5OD#^:%|
ejoN*ސsbW=Rͦ<
J5bFNsc
[0Bj>1U;Ȓ~dG|EAƨdHςNrޔ\GTtgWal=~B6<'>NmiEuʦwML*.8D),qf~ X&xqn
p\o"89[y+kzml4lc#kޟjlnքI= F=c-Ii
yQLT"z[Lń"I|WdyVȓE'zP)v03sʰ.9b)cG̘,x)<2At^$vϢDj :S8!g( \86bTBc+] {z=oׇ01mj9u̞I||ƕ_X߂3x)_04\ks*pZA{X](p.9hB$ `v\ a3[. hD -z9Ղ;c)H{$È̻3P=7i$ײ
ڭ
"08i[^n!۟nӎ2^nbdc B&R ˯ד~9c~Ԍ"#Snf`D6sɟtaFa4